Posted by Michael Wonder on 09 Jan 2026
Annexon submits tanruprubart marketing authorisation application to the EMA for Guillain-Barré syndrome
8 January 2026 - BLA submission with US/European data from FORWARD trial planned in 2026
Annexon today announced it has submitted a marketing authorisation application to the EMA for tanruprubart for the treatment of Guillain-Barré syndrome.
